Results 51 to 60 of about 53,113 (297)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

The importance for immunoregulation for long-term cancer control. [PDF]

, 2017
Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy.
Alberto Fusi, Angus Dalgleish, Chan TA, Chen RW, Fryer RA, Hyunjoon K, Weber J   +6 more
core   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source

The Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lungs: Insights from the LANCE Pilot Study

Biomedicines
Background: Large cell neuroendocrine carcinoma (LCNEC) presents significant treatment challenges due to its rarity and limited therapeutic options.
Georgios Evangelou, Ioannis P. Trontzas, Ioannis Gkiozos, Ioannis Vamvakaris, Christina Paraskeva, Maria Grammoustianou, Georgia Gomatou, Ioannis Tsamis, Ioannis Vathiotis, Maximillian Anagnostakis, Vasiliki Koliaraki, Kostas Syrigos   +11 more
doaj   +1 more source

Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

BMC Gastroenterology, 2021
Background Hepatocellular carcinoma (HCC) with major portal vein tumor thrombus (Vp4 PVTT) is an extremely advanced tumor with limited treatment options.
Shohei Komatsu, Yoshimi Fujishima, Masahiro Kido, Kaori Kuramitsu, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto   +7 more
doaj   +1 more source

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Pharmaceuticals, 2022
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro   +6 more
doaj   +1 more source

Role of noninvasive molecular imaging in determining response [PDF]

, 2018
The intersection of immunotherapy and radiation oncology is a rapidly evolving area of preclinical and clinical investigation. The strategy of combining radiation and immunotherapy to enhance local and systemic antitumor immune responses is intriguing ...
Marciscano, Ariel E, Thorek, Daniel L.J.
core   +2 more sources

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, EarlyView.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

Pure Red Cell Aplasia Induced by Atezolizumab in a Patient with Small-Cell Lung Cancer Successfully Treated with Steroid Therapy: A Case Report

Case Reports in Oncology, 2023
Introduction: Combination therapy of atezolizumab and chemotherapy has become the standard treatment for small-cell lung cancer. Immune-related adverse events (irAEs) can occur during immune checkpoint inhibitor administration.
Keita Kawakado, Shunsuke Ito, Kento Kono, Yuki Mitarai, Takashi Yanagawa, Makoto Nagasaki   +5 more
doaj   +1 more source

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]

, 2018
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core   +1 more source